Compare iShares MSCI France ETF (EWQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI France ETF trades at $45.16, while Zimmer Biomet Holdings Inc trades at $90.17 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares MSCI France ETF pays none, and iShares MSCI France ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| EWQ | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $107.71 |
52-Week Low | $41.43 | $79.58 |
Market Cap | — | $17.44B |
Enterprise Value | — | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI France ETF (EWQ) is trading at $45.16, up 0.27% on the day, while exhibiting a bearish technical signal with 11 sell signals versus 6 buy signals. The fund faces headwinds from European Central Bank rate hikes and energy market volatility driven by Middle East tensions, though it offers exposure to French technology investments and a scheduled $1.09 dividend in June 2026.
Outlook remains cautious amid macroeconomic uncertainty, with investment opportunity tied to France's €13 billion tech sovereignty push and AI investments, balanced against risks from energy price shocks, potential job losses in key EU sectors, and geopolitical trade tensions that could impact European equities.
Zimmer Biomet (ZBH) trades at $92.94, up 2.1% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 70% gross margin and positive cash flow trends, though net income margin has declined from 13.8% in 2023 to 8.6% in 2025. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase, indicating management confidence.
ZBH presents a moderate growth opportunity with a consensus price target of $97.67, offering ~5% upside. Risks include rising debt levels and competitive pressures in medical devices. Analyst sentiment is mixed with 40% buy ratings, but institutional activity and strategic acquisitions support a stable outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
